An ophthalmic pharmaceutical company, focused on the development and commercialization of products for serious diseases and conditions of the eye.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
It should go up after the next earnings report as Bepreve starts to grow, and Xibrom continues to lead the market. Another catalyst will be the Xibrom-once daily mid 2010 approval date which will cement Xibrom's market share. With Novartis finishing up scooping Alcon, I'm sure big pharma will by eyeing (pardon the pun) Ista in the next couple of years, hopefully well after Ista grows in earnings and stock price. With a good pipeline and positive 2010 income on the way, the stock price is much undervalued. I'm very bullish at these levels.